細菌疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按疫苗類型、患者年齡層、分銷管道、給藥途徑、地區和競爭格局分類，2021-2031年

全球細菌疫苗市場預計將從 2025 年的 71.9 億美元成長到 2031 年的 109.4 億美元，複合年成長率達到 7.25%。

細菌疫苗是一種旨在誘導人體對特定細菌感染疾病產生主動免疫的生物製藥。除了腦膜炎和肺炎等感染疾病的增加外，強力的政府免疫政策也推動了細菌疫苗市場的成長。世界衛生組織和聯合國兒童基金會預測，到2024年，這些政策將使全球百白破疫苗（DTP3）的接種率達到85%。然而，疫苗儲存和分銷所需的複雜且成本高昂的低溫運輸物流是一大障礙，這往往限制了開發中國家）的市場准入。

市場促進因素

細菌疫苗市場的主要促進因素是日益嚴重的抗菌素抗藥性（AMR）威脅。這使得疫苗成為減少對抗生素依賴的關鍵手段，並能夠預防肺炎和腦膜炎等感染疾病。世界衛生組織2024年10月的報告指出，針對23種病原體的疫苗每年可減少25億劑抗生素的使用，凸顯了疫苗在合理使用抗菌藥物和保障國家衛生安全方面的重要作用。同時，結合疫苗和重組疫苗的技術進步透過擴大血清型覆蓋範圍和獲得持久免疫力，正在拓展市場潛力。默克公司於2024年6月獲得美國食品藥物管理局（FDA）核准的21價肺炎鏈球菌感染結合疫苗證明了這一點，多價疫苗製劑能夠提供更廣泛的保護，抵禦多種細菌菌株。這些創新得益於諸如全球疫苗免疫聯盟（Gavi）的「2024非洲疫苗生產加速器」等投資項目，該項目是一項10億美元的舉措，旨在推出新興市場的疫苗生產。

市場挑戰

由於嚴格的低溫運輸要求，全球細菌疫苗市場面臨許多限制。這些疫苗從生產到患者接種的整個過程中都需要精確的溫度控制，因此專用的儲存和運輸設施必不可少。在基礎設施欠缺發展的地區，維持溫度控制在技術上極具挑戰性，且成本高昂，導致營運成本增加，利潤率下降。這種經濟負擔阻礙了疫苗進入對價格敏感的發展中市場，因為在這些市場，物流成本會降低投資收益率。這些基礎設施的限制阻礙了市場滲透，導致供應鏈效率低、疫苗浪費，以及在疾病高發生率地區疫苗取得受限。全球疫苗免疫聯盟（Gavi）2024年發布的報告生動地揭示了低收入國家1020萬未接種疫苗兒童的現狀，充分說明了這些持續存在的疫苗獲取障礙。

市場趨勢

該市場正受到兩大趨勢的顯著影響。首先，結構疫苗學與人工智慧結合的抗原發現技術正在變革研發模式，突破傳統經驗方法的限制，實現細菌免疫原的精確電腦設計。例如，GoogleDeepMind的AlphaFold 3將生物分子交互作用預測的準確率提高了50%，加速了細菌蛋白標靶的識別，並降低了臨床前研究的失敗率。其次，人們越來越關注B族鏈球菌（GBS）的母體疫苗接種研究，旨在透過垂直免疫降低新生兒死亡率。這旨在克服資源匱乏地區無法在分娩期間提供預防性抗生素的限制。 MinervaX公司正在擴大GBS疫苗的生產規模，並計劃於2024年9月開展試驗，這凸顯了該領域致力於將母體疫苗接種確立為預防嚴重新生兒細菌感染疾病的標準做法的努力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細菌疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 疫苗類型（百日咳疫苗、破傷風疫苗、白喉疫苗、肺炎鏈球菌疫苗、腦膜炎雙球菌疫苗、傷寒疫苗、結核病疫苗、霍亂疫苗、志賀氏桿菌感染疫苗、其他）
  • 病患年齡層（兒童疫苗（嬰兒、兒童）、青少年疫苗、成人疫苗、老年人疫苗）
  • 分銷管道（政府機構和專案、醫院和診所、零售藥局、網路藥局、其他）
  • 依給藥途徑（注射疫苗、口服疫苗、鼻噴疫苗）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細菌疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細菌疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細菌疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細菌疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲細菌疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球細菌疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• GSK plc
• Novartis AG
• Mylan NV
• Sanofi SA
• Boehringer Ingelheim International GmbH.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Bharat Biotech International Ltd
• Serum Institute of India Pvt. Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Bacterial Vaccines Market is projected to expand from USD 7.19 billion in 2025 to USD 10.94 billion by 2031, achieving a 7.25% CAGR. Bacterial vaccines are biological agents designed to stimulate active immunity against specific bacterial infections. This growth is driven by the increasing incidence of infectious diseases like meningitis and pneumonia, alongside strong government immunization initiatives, which contributed to an 85% global coverage for the DTP3 vaccine in 2024 according to WHO and UNICEF. However, a major impediment is the intricate and costly cold chain logistics required for vaccine storage and distribution, which often limits market access in developing countries where the disease burden is most severe.

Market Driver

A key driver for the bacterial vaccines market is the growing threat of antimicrobial resistance (AMR), positioning vaccines as crucial tools to reduce antibiotic dependence by preventing infections like pneumonia and meningitis. The WHO's October 2024 report indicated that vaccines against 23 pathogens could annually cut antibiotic doses by 2.5 billion, underscoring their essential role in antimicrobial stewardship and national health security. Simultaneously, technological progress in conjugate and recombinant vaccines is broadening market potential through improved serotype coverage and durable immunity. High-valency formulations offer wider protection against various bacterial strains, as demonstrated by Merck's June 2024 FDA approval of a 21-valent conjugate vaccine for pneumococcal disease. These innovations are bolstered by investments like Gavi's 2024 launch of the African Vaccine Manufacturing Accelerator, a US$1 billion initiative to foster vaccine production in emerging markets.

Market Challenge

The global bacterial vaccines market faces a significant restraint due to the stringent cold chain requirements. These vaccines demand precise temperature control throughout their journey, from manufacturing to patient, necessitating specialized storage and transport. In regions with poor infrastructure, ensuring temperature integrity is technically challenging and financially burdensome, raising operational costs and reducing profit margins. This economic strain hinders expansion into price-sensitive developing markets, where logistical overheads diminish ROI. Such infrastructure rigidities impede market penetration, leading to supply chain inefficiencies, vaccine wastage, and restricted access in areas with high disease incidence. Gavi's 2024 report on 10.2 million zero-dose children in lower-income countries exemplifies these persistent access barriers.

Market Trends

The market is significantly influenced by two key trends. Firstly, structural vaccinology combined with AI for antigen discovery is transforming R&D by enabling precise computational design of bacterial immunogens, surpassing traditional empirical approaches. Google DeepMind's AlphaFold 3, for instance, boosts biomolecular interaction prediction accuracy by 50%, accelerating the identification of bacterial protein targets and reducing preclinical attrition rates. Secondly, there's a growing focus on maternal immunization research for Group B Streptococcus (GBS) to decrease neonatal mortality via vertical immunity. This aims to overcome the limitations of inaccessible intrapartum antibiotic prophylaxis in low-resource settings. MinervaX's September 2024 manufacturing scale-up for GBS vaccine trials highlights the sector's commitment to establishing maternal vaccination as a standard for preventing severe neonatal bacterial infections.

Key Market Players

• Pfizer Inc.
• GSK plc
• Novartis AG
• Mylan N.V.
• Sanofi SA
• Boehringer Ingelheim International GmbH.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Bharat Biotech International Ltd
• Serum Institute of India Pvt. Ltd

Report Scope

In this report, the Global Bacterial Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bacterial Vaccines Market, By Vaccine Type

• Pertussis (Whooping Cough) Vaccines
• Tetanus Vaccines
• Diphtheria Vaccines
• Pneumococcal Vaccines
• Meningococcal Vaccines
• Typhoid Vaccines
• Tuberculosis (TB) Vaccines
• Cholera Vaccines
• Shigellosis Vaccines
• Others

Bacterial Vaccines Market, By Patient Age Group

• Pediatric Vaccines
• Adolescent Vaccines
• Adult Vaccines
• Geriatric Vaccines

Bacterial Vaccines Market, By Distribution Channel

• Government Agencies and Programs
• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

Bacterial Vaccines Market, By Route of Administration

• Injectable Vaccines
• Oral Vaccines
• Nasal Vaccines

Bacterial Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Vaccines Market.

Available Customizations:

Global Bacterial Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bacterial Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others)
  • 5.2.2. By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines)
  • 5.2.3. By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.4. By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Bacterial Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Patient Age Group
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Route of Administration
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bacterial Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Patient Age Group
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By Route of Administration
  • 6.3.2. Canada Bacterial Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Patient Age Group
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By Route of Administration
  • 6.3.3. Mexico Bacterial Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Patient Age Group
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By Route of Administration

7. Europe Bacterial Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Patient Age Group
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bacterial Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Patient Age Group
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By Route of Administration
  • 7.3.2. France Bacterial Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Patient Age Group
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By Route of Administration
  • 7.3.3. United Kingdom Bacterial Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Patient Age Group
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By Route of Administration
  • 7.3.4. Italy Bacterial Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Patient Age Group
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By Route of Administration
  • 7.3.5. Spain Bacterial Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Patient Age Group
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Bacterial Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Patient Age Group
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bacterial Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Patient Age Group
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By Route of Administration
  • 8.3.2. India Bacterial Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Patient Age Group
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By Route of Administration
  • 8.3.3. Japan Bacterial Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Patient Age Group
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By Route of Administration
  • 8.3.4. South Korea Bacterial Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Patient Age Group
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By Route of Administration
  • 8.3.5. Australia Bacterial Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Patient Age Group
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Bacterial Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Patient Age Group
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Route of Administration
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bacterial Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Patient Age Group
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By Route of Administration
  • 9.3.2. UAE Bacterial Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Patient Age Group
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By Route of Administration
  • 9.3.3. South Africa Bacterial Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Patient Age Group
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By Route of Administration

10. South America Bacterial Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Patient Age Group
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Route of Administration
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bacterial Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Patient Age Group
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By Route of Administration
  • 10.3.2. Colombia Bacterial Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Patient Age Group
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By Route of Administration
  • 10.3.3. Argentina Bacterial Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Patient Age Group
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bacterial Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GSK plc
• 15.3. Novartis AG
• 15.4. Mylan N.V.
• 15.5. Sanofi SA
• 15.6. Boehringer Ingelheim International GmbH.
• 15.7. Merck & Co., Inc.
• 15.8. F. Hoffmann-La Roche Ltd.
• 15.9. Bristol-Myers Squibb Company
• 15.10. Bharat Biotech International Ltd
• 15.11. Serum Institute of India Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer